Dr. Gary D. Lopaschuk Degrees BSc, University of British Columbia, Canada PhD, University of British Columbia, Canada
Current position Scientific Director, Mazankowski Alberta Heart Institute, University of Alberta Distinguished University Professor, Departments of Pediatrics and Pharmacology, University of Alberta Alberta Heritage Foundation for Medical Research Scientist Appointments Project Leader, CFI "Cardiovascular Translational Research Centre" Director of Research, Department of Pediatrics, University of Alberta BioAlberta Leadership in Science & Innovation Award Canadian Cardiovascular Society Research Achievement Award Medical Advisory Board, Heart and Stroke Foundation of Alberta, N.W.T. and Nunavut, member Chair, Personal Program Review Task Force, Heart and Stroke Foundation of Canada NIH "Metabolism and Myocardial Ischemia" Study Section, Member Chairman, Scientific Review Committee, Heart and Stroke Foundation of Alberta Editorial Board, Circulation Research Editorial Board, J Clinical Investigation Associate Editor, Americal Journal of Physiology, Heart Associate Editor, Canadian Journal of Physiology and Pharmacology Editorial Board, Cardiovascular Research Editorial Board, Basic Research in Cardiology Scientific Advisory Committee, Women's and Children's Health Research Institute Consulting experience Extensive consulting track record with pharma and named on hundreds of patents.
Biography Dr. Gary D. Lopaschuk is a Distinguished University Professor of Pediatrics at the University of Alberta, Edmonton
He is a Cardiovascular Researcher whose research focuses on the regulation of fatty acid oxidation in the heart, and the mechanism by which high rates of fatty acid oxidation contribute to heart disease and heart failure.
is also examining how alterations in fatty acid metabolism contribute to cardiovascular disease in the diabetic.
At a molecular level he
has characterized a number of key enzymes important in the regulation of cardiac fatty acid oxidation.
is also developing a number of therapeutic strategies that involve optimizing energy metabolism in the heart that can be used to prevent the development of heart disease, and that can also be used to treat heart failure.
research has resulted in the publication of over 330 original research articles, and he
has been recognized by awards such as the Canadian Cardiovascular Research Achievement Award and the International Academy of Cardiovascular Sciences Research Achievement Award
Dr. Lopaschuk is an Alberta Innovates Health Solution Scientist, and is a Fellow of the Royal Society of Canada.
He serves on a number of journal editorial boards, including Circulation Research, Journal of Clinical Investigation, American Journal of Physiology, Cardiovascular Research, Journal of Molecular and Cellular Cardiology, Canadian Journal of Physiology and Pharmacology, Heart and Metabolism, and Cardiovascular Drugs and Therapy.
He is also the President and CEO of a biotechnology company (Metabolic Modulators Research Ltd.), that is developing novel drugs to treat heart disease that optimize energy metabolism in the heart.